Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 7% – Should You Sell?

Posted by Brian Himes on Jul 22nd, 2026

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report)’s stock price fell 7% on Monday . The stock traded as low as $1.07 and last traded at $1.07. Approximately 795,872 shares traded hands during mid-day trading, an increase of 32% from the average session volume of 601,572 shares. The stock had previously closed at $1.15.

Analyst Ratings Changes

PLRX has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Friday. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 19th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $3.00.

Get Our Latest Stock Analysis on PLRX

Pliant Therapeutics Stock Up 0.9%

The company has a market cap of $68.11 million, a PE ratio of -0.60 and a beta of 1.21. The company has a 50-day moving average of $1.16 and a 200-day moving average of $1.23.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. As a group, equities analysts predict that Pliant Therapeutics, Inc. will post -1.31 EPS for the current year.

Institutional Investors Weigh In On Pliant Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Monaco Asset Management SAM lifted its position in shares of Pliant Therapeutics by 135.7% during the 4th quarter. Monaco Asset Management SAM now owns 1,938,747 shares of the company’s stock worth $2,365,000 after buying an additional 1,116,054 shares in the last quarter. BML Capital Management LLC bought a new position in shares of Pliant Therapeutics in the fourth quarter valued at approximately $1,886,000. Hennion & Walsh Asset Management Inc. increased its position in shares of Pliant Therapeutics by 15.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 113,383 shares of the company’s stock valued at $138,000 after acquiring an additional 15,349 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Pliant Therapeutics by 8.8% during the third quarter. JPMorgan Chase & Co. now owns 2,130,489 shares of the company’s stock worth $3,153,000 after acquiring an additional 172,056 shares during the period. Finally, HRT Financial LP bought a new stake in Pliant Therapeutics during the fourth quarter worth $39,000. 97.30% of the stock is owned by institutional investors.

Pliant Therapeutics Company Profile

(Get Free Report)

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).